Chikungunya virus control: Is a vaccine on the horizon?

The Lancet

Volumn 384, Issue 9959, 2014, Pages 2008-2009

  Powers, Ann M ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE; VIRUS VACCINE;

ARBOVIRUS; CHIKUNGUNYA; CHIKUNGUNYA ALPHAVIRUS; DENGUE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; IMMUNOGENICITY; INFECTION CONTROL; LYME DISEASE; MALARIA; NOTE; WEST NILE FLAVIVIRUS; FEMALE; IMMUNOLOGY; MALE;

CHIKUNGUNYA VIRUS; FEMALE; HUMANS; MALE; VIRAL VACCINES;

EID: 84919844537     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(14)61290-3     Document Type: Note

References (16)

1. WHO Dengue and severe dengue fact sheet http://www.who.int/mediacentre/factsheets/fs117/en/ (accessed Aug 8, 2014).
2. US Centers for Disease Control and Prevention Reported cases of Lyme disease by year, United States, 2003-2012 http://www.cdc.gov/lyme/stats/chartstables/casesbyyear.html (accessed July 24, 2014).
3. NP Lindsey, JA Lehman, JE Staples, M Fischer West Nile virus and other arboviral diseases - United States, 2012 MMWR Morb Mortal Wkly Rep 62 2013 513 517
4. M Fischer, JE Staples Arboviral Diseases Branch Zoonotic Infectious Diseases Notes from the field: chikungunya virus spreads in the Americas - Caribbean and South America, 2013-2014 MMWR Morb Mortal Wkly Rep 63 2014 500 501
5. P Gerardin, V Guernier, J Perrau et al. Estimating chikungunya prevalence in La Reunion island outbreak by serosurveys: two methods for two critical times of the epidemic BMC Infect Dis 8 2008 99
6. MK Soumahoro, PY Boelle, BA Gauzere et al. The chikungunya epidemic on La Reunion island in 2005-2006: a cost-of-illness study PLoS Negl Trop Dis 5 2011 e1197
7. GM Vazquez-Prokopec, LF Chaves, SA Ritchie, J Davis, U Kitron Unforeseen costs of cutting mosquito surveillance budgets PLoS Negl Trop Dis 4 2010 e858
8. R Edelman, CO Tacket, SS Wasserman, SA Bodison, JG Perry, JA Mangiafico Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218 Am J Trop Med Hyg 62 2000 681 685
9. CH Hoke Jr, J Pace-Templeton, P Pittman et al. US military contributions to the global response to pandemic chikungunya Vaccine 30 2012 6713 6720
10. L-J Chang, KA Dowd, FH Mendoza the VRC 311 Study Team Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial Lancet 2014 S0140-6736(14)61185-5 published online Aug 15.
11. W Akahata, ZY Yang, H Andersen et al. A virus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection Nat Med 16 2010 334 338
12. FE Andre How the research-based industry approaches vaccine development and establishes priorities Dev Biol (Basel) 110 2002 25 29
13. ES Pronker, TC Weenen, H Commandeur, EH Claassen, AD Osterhaus Risk in vaccine research and development quantified PLoS One 8 2013 e57755
14. RT Mahoney, DP Francis, NM Frazatti-Gallina et al. Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butantan, Sao Paulo, Brazil Vaccine 30 2012 4892 4896
15. DL Douglas, DA DeRoeck, RT Mahoney, O Wichmann Will dengue vaccines be used in the public sector and if so, how? Findings from an 8-country survey of policymakers and opinion leaders PLoS Negl Trop Dis 7 2013 e2127
16. K Sergon, AA Yahaya, J Brown et al. Seroprevalence of chikungunya virus infection on Grande Comore Island, Union of the Comoros, 2005 Am J Trop Med Hyg 76 2007 1189 1193